Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

Abstract (250 word limit; word count 240) Introduction: Exon 19 deletions and exon 21
L858R mutation of the epidermal growth factor receptor (EGFR) predict activity of EGFR …

Introduction: Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

Introduction: Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

METHODS The efficacy of erlotinib in individual patients with rare EGFR mutations from the
MERIT, SATURN, TITAN, TRUST, ATLAS, BeTa, and FASTACT-2 trials was analyzed and …

METHODS The efficacy of erlotinib in individual patients with rare EGFR mutations from the
MERIT, SATURN, TITAN, TRUST, ATLAS, BeTa, and FASTACT-2 trials was analyzed and …

Introduction: Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung
Cancer Whose Tumors Harbor Uncommon EGFR Mutations | CiNii Research CiNii 国立情報学 …

Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …